DPP4 and acquired epidermolysis bullosa: One possible explanation for the paradoxical development of EBA in the setting of DPP-4 inhibition is that DPP-4 blockade may not fully suppress Th1/Th17 activation in certain inflammatory states, allowing residual or compensatory pathways to sustain a Th1/Th17-dominant environment despite pharmacologic inhibition.